PRIMO 2025 | Anti-LAG-3 and anti-PD-1 combination shows promising results in advanced melanoma treatment
Merrick Ross
• 7 Feb 2025
Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the promising results of a Phase I trial (NCT03005782) combining anti-LAG-3 and anti-PD-1 in advanced melanoma, achieving a significant pathologic response rate of approximately 67%, noting that the combination is well-tolerated. He speculates that the results of a large adjuvant therapy trial combining anti-LAG-3 with anti-PD-1, which has already been completed, may be presented at ASCO this year. This interview took place at the PRIMO 2025 congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
